Fierce Pharma

Citing a rosy view of the U.S. economy's potential for growth over the next several years, British Big Pharma AstraZeneca is substantially boosting its investment in manufacturing and R&D in the country.

As National Diabetes Month gets underway, StrideMD is among the diabetes care providers, tech developers and drugmakers helping raise awareness of the condition.

After a series of acquisitions and an activist investor's accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit,

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals' bid to win full approval for its liver disease drug Ocaliva has come up short.

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns” in the road ahead, Bayer is confident that the course it's laid out thus far “is the right one,” CEO Bill Anderson mused on the company's third-quarter earnings call.

While personally “disappointed” about the election's outcome, current FDA Commissioner Robert Califf, M.D., has laid out the qualities that he hopes his successor will have.

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward layoffs and scrap further development of its seizure med Ztalmy.

As a wave of patent expirations encroaches upon many of the world's top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term.

Zimmer Biomet has hired The Terminator to tell the world that “if you rest, you rust.” The manufacturer of orthopedic medtech products is getting

Following an impressive data drop this summer highlighting the potential for Eli Lilly's tirzepatide to stave off progression to Type 2 diabetes in